Efficacy of α(s1)-casein hydrolysate on stress-related symptoms in women

• Published in: European journal of clinical nutrition 2007, Vol.61 (4), p.536-541
• Main Authors: Kim, J.H, Desor, D, Kim, Y.T, Yoon, W.J, Kim, K.S, Jun, J.S, Pyun, K.H, Shim, I
• Format: Article
• Language: English
• Subjects: alphaS1-casein; Computer Science; cross-sectional studies; hydrolysates; Life Sciences; nutritional intervention; psychological stress; questionnaires; women
• ISSN: 0954-3007; 1476-5640
• DOI: 10.1038/sj.ejcn.1602553

Objective: To examine the effects of (alpha)s1-casein hydrolysate on females with stress-related symptoms. Design: Double-blind, randomized, crossover, placebo-controlled trial. Setting: The (alpha)s1-casein hydrolysate was manufactured by INGREDIA (Arras, France) and the placebo was manufactured by DIETAROMA (Bourg, France). Study was designed and performed at PROCLAIM (Rennes, France), and the statistical analyses were performed by D Desor (Nancy, France). Subjects: A total of 63 female volunteers suffering from at least one disorder that may be related to stress such as anxiety, sleep problems and general fatigue. Interventions: A total of 63 volunteers participated in a double-blind, randomized, crossover, placebo-controlled study. Subjects were randomly allocated to receive either tablets containing (alpha)s1-casein hydrolysate or placebo at the dose of 150 mg/day for 30 days. After a 3 weeks washout period, they were crossed over for a new 30-day period of tablets intake. The outcome measure was a questionnaire including 44 items of symptoms that may be related stress in which the severity of each sign was evaluated using a 10-degree scale. These measures were studied repeatedly at the day of 0, 15 and 30 after the start of each interventional period. Results: The 30-day treatment by (alpha)s1-casein hydrolysate in females with stress-related symptoms reduced their symptoms, particularly in digestion (P